Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
Intravenous (IV) ketamine is effective in adults resistant to depression. The response was similar to that seen in younger patients, two new studies show.
Read Full NewsFrontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.
GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.
Fear of Movement, Central Sensitization May Worsen Outcomes in Gout
FDA Extends PDUFA Date for Reproxalap in Dry Eye Disease to March 2026
FDA Accepts, Grants Priority Review to Veligrotug BLA for Thyroid Eye Disease
Weight-Loss Interventions Improve Psoriasis Severity, Quality of Life
1.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
2.
What Role Should Genomic Classifier Testing Play in Prostate Cancer?
3.
New study elucidates obesity's role in fueling breast cancer progression
4.
Remote monitoring can improve recovery from cancer surgery
5.
Neural networks and label-free microscopy enable accurate detection of pancreatic tumors
1.
The Role of the Oncology Pharmacist: From Treatment to Trials and Beyond
2.
Seeing the Unseen: The Benefits of Early Stage Breast Cancer Ultrasound
3.
Rare Malignant Ovarian Tumors: A Comprehensive Review for Clinicians
4.
Understanding Histiocytosis: Symptoms, Causes, and Treatment Options
5.
Exploring the Potential of Xospata: A New Frontier in Cancer Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part VII
2.
L858R Mutation- An Overview of Retrospective Cohort Study in Advanced NSCLC Patients
3.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge